Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 510

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 12
Chunk 510
---
 outstanding stock options, warrants and equity incentive plans.

On
November 11, 2021, the Company increased the number of authorized shares of common stock, $0.0001 par value per share, to 45,000,000
from 25,000,000.

On
January 25, 2022, the Company effected a one-for-two (1:2) reverse stock split whereby the Company (i) decreased the number of issued
and outstanding shares of common stock, $0.0001 per share, from 13,076,608 to 6,538,304 and (ii) decreased by a ratio of one-for two
(1:2) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split
were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts
have been retroactively adjusted as of the earliest period presented in the financial statements to reflect the reverse stock split.

On
June 14, 2024, the Company increased the number of authorized shares of common stock, $0.0001 par value per share, to 125,000,000 from
45,000,000.

On
June 14, 2024, the Company effected a fifteen-for-four (15:4) forward stock split whereby the Company (i) increased the number of issued
and outstanding shares of common stock, $0.0001 par value per share, from 8,033,706 to 30,126,413 and (ii) increased by a ratio of fifteen-for-four
(15:4) the number of retroactively issued and outstanding shares of common stock. Proportional adjustments for the forward stock split
were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts
have been retroactively adjusted as of the earliest period presented in the financial statements to reflect the forward stock split.

    F-7

JUPITER
NEUROSCIENCES, INC.

NOTES
TO FINANCIAL STATEMENTS

December
31, 2024 and 2023

Note
2 – Significant Accounting Policies

Basis
of presentation and Going Concern

The
financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States
of America (“U.S. GAAP”). U.S GAAP contemplates continuation of the Company